AIM Highlights Ampligen Potential in Pancreatic Cancer
OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...
Immuno-Oncology
Advertisement
MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC
CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...
OSE to Present Phase 2 Tedopi Data in Metastatic NSCLC
NANTES, France — September 23, 2026 OSE Immunotherapeutics announced that topline results from the Combi-TED Phase 2 trial of...
SystImmune Advances SI-B037 Into Phase 1/1b Trial
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Akeso to Present Ivonescimab Phase 3 Data at ESMO 2026
Hong Kong, China, September 21, 2026 Akeso, Inc. has announced that nearly 30 clinical studies from its innovative biopharmaceutical...
Advertisements
Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
MAIA Biotechnology Doses First U.S. Patient in THIO-101
CHICAGO — September 16, 2026 MAIA Biotechnology, Inc. announced that the first U.S. patient has been dosed in the...
Elanco Advances Pet Health Innovation as Tick Season Expands
Indianapolis, Indiana, September 15, 2026 Elanco Animal Health is reporting continued momentum in its pet health innovation portfolio as...
Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
Harbour BioMed Partner Solstice Oncology Raises $225M
Shanghai, China, September 10, 2026 Solstice Oncology, a partner of Harbour BioMed, has announced a $225 million Series A...
Advertisement
